Tag: Acs

Every 34 seconds, one American experiences a coronary event, underscoring the critical importance of proper treatment strategies for acute coronary syndrome (ACS). However, a common misconception arises regarding the use of clot-busting drugs: a key principle of modern cardiology dictates that you cannot give fibrinolytics in NSTEMI, or Non-ST-Elevation Myocardial Infarction.

For patients with Acute Coronary Syndrome (ACS), dual antiplatelet therapy (DAPT) including ticagrelor is typically recommended for 12 months. Understanding **how long is the treatment for ticagrelor?** is crucial, as the exact duration varies significantly based on the patient's specific medical history, risk factors, and clinical event.

According to major clinical trials, ticagrelor is a potent antiplatelet drug proven to reduce cardiovascular events in high-risk patients, especially when compared to clopidogrel. This guide explains what is the use of ticagrelor tablet, detailing its role in preventing life-threatening heart and brain events.